OS Therapies FY2025 EPS Cut by Brookline Capital Management

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Equities researchers at Brookline Capital Management reduced their FY2025 earnings per share estimates for shares of OS Therapies in a note issued to investors on Tuesday, November 18th. Brookline Capital Management analyst K. Raja now anticipates that the company will earn ($0.76) per share for the year, down from their prior forecast of ($0.61). The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ Q4 2025 earnings at ($0.18) EPS, FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.01) EPS and FY2029 earnings at $0.47 EPS.

A number of other equities research analysts have also recently commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Monday. Lake Street Capital lowered their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, OS Therapies has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

OS Therapies Stock Down 4.6%

Shares of OSTX stock opened at $1.65 on Thursday. The stock has a market cap of $58.10 million, a P/E ratio of -2.01 and a beta of -4.10. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The business has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $1.90.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On OS Therapies

Several hedge funds have recently modified their holdings of OSTX. Susquehanna International Group LLP purchased a new stake in shares of OS Therapies during the third quarter worth about $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the third quarter valued at approximately $40,000. Ground Swell Capital LLC acquired a new stake in OS Therapies during the third quarter worth approximately $40,000. CM Management LLC grew its stake in OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after acquiring an additional 25,000 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in OS Therapies in the 2nd quarter valued at $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.